Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ectocervical CIN1 or CIN2 as verified by local pathology (biopsy) obtained within the last month~* Satisfactory colposcopy examination including:~  * visibility of entire transformation zone including the squamocolumnar junction and~ * visibility of entire lesion margin~* Negative endocervical os by colposcopy~* Colposcopical visible lesion at visit 2, before treatment~* Patients with an average sized uterine cervix (approximately 27mm diameter) suitable for application of the Klemcap~* Age 18 or above~* Written informed consent signed~Exclusion Criteria:~* Previous treatment of CIN or invasive disease~* Lesion(s) extending to the vaginal vault~* Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant cells on cytology or histology or other suspicion of either micro-invasive or invasive disease~* Suspicion of endocervical disease on colposcopy~* Current severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per colposcopy and clinical examination~* Undiagnosed vaginal bleeding~* History of toxic shock syndrome~* Known or suspected porphyria~* Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate or aminolevulinic acid)~* Pregnancy, or intention to become pregnant during the study period~* Nursing~* Childbirth or miscarriage within six weeks of enrolment~* Use of heart pacemaker~* Participation in other clinical studies either concurrently or within the last 30 days~* Risk of poor protocol compliance. Patient participation should be considered with respect to living far away from the hospital, plans for moving to another city/state, frequent travelling, planning to become pregnant, drug abuse/alcoholic, difficult working hours, family obligations, other illness (e.g. psychiatric), etc.~* Unwillingness to use adequate birth control (not abstinence) from screening until last PDT~* Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HAL 5% with illumination (Type: EXPERIMENTAL): HAL PDT 5%
- HAL 1% with illumination (Type: EXPERIMENTAL): HAL PDT 1%
- HAL 0.2% with illumination (Type: EXPERIMENTAL): HAL PDT 0.2%
- Placebo ointment without illumination (Type: PLACEBO_COMPARATOR): Placebo without illumination

Based on this trial design, predict the completion outcome and termination type (if applicable).